NCT06579053已完成1 期
An Open-label, Randomized, Single-dose, Two-period Crossover Design on Evaluating the Bioequivalence of Spironolactone Tablets 100mg (by SPH Sine Pharmaceutical Laboratories Co.,Ltd) and ALDACTONE® Tablets 100mg (by GD SEARLE LLC) in Healthy Adult Volunteers Under Fasting and Fed Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 64
- 试验地点
- 1
- 主要终点
- Cmax
研究概览
简要总结
The goal of this clinical trial is to Evaluate the Bioequivalence of Spironolactone Tablets 100mg (by SPH Sine Pharmaceutical Laboratories Co.,Ltd) and ALDACTONE® tablets 100mg (by GD SEARLE LLC) in Chinese Healthy Adult Volunteers under Fasting and Fed Conditions. It will also learn about the safety of the two drugs.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Other
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 40 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •18 years old ≤ age ≤ 40 years old, male or female;
- •Weight: ≥ 50 kg for male and ≥ 45 kg for female; body mass index (BMI) in the range of 19-26 kg/m2 (including 19 and 26);
- •No history of heart, liver, kidney, gastrointestinal, nervous system, mental abnormalities and metabolic abnormalities, no history of allergy to agents, no history of serious infections and serious injuries, etc;
- •Physical examination, vital signs examination, electrocardiogram examination, and laboratory examination of important indicators are normal or within the range considered acceptable by the sponsor/investigator;
- •No parenting plan and access to reliable contraception during the trial and within 3 months of the last dose;
- •Fully understand the purpose and requirements of the trial, voluntarily participate in the clinical trial and sign the ICF, and be able to complete the entire trial process according to the trial requirements.
排除标准
- •Persons with a known history of allergy, allergic disorder or hypersensitivity to the test product and any of its components or related agents;
- •Persons with a clear history of central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, hematological system, metabolic disorders (e.g. hyperkalemia) or other diseases that are not suitable for participation in clinical trials (e.g. history of psychiatric disorders, etc.);
- •Those who have donated blood or lost ≥ 400 mL of blood within 3 months prior to enrollment;
- •Those who have taken any medication within 2 weeks prior to screening;
- •Those who have participated in other drug clinical trials within 3 months prior to enrollment;
- •current or former drug abuser or alcohol addict who consumes alcohol at least 2 times a day or 14 or more times a week, or is an avid drinker (1 drink defined as 125 mL of wine, 220 mL of beer or 50 mL of liquor; alcoholism defined as 5 or more drinks in approximately 2 hours);
- •Those who smoked more than 10 cigarettes per day during the 3 months prior to screening;
- •Hepatitis B surface antigen (HBsAg), HCV antibodies, syphilis spirochete antibodies and HIV antibody-positive persons;
- •Those with positive drug abuse screening results or alcohol breath test results;
- •Those with positive pregnancy test results(female)；
- •Those who have other factors that the investigator considers unsuitable for participation in the trial.
研究组 & 干预措施
Test product
Experimental
Spironolactone Tablets, 100 mg/tablet, to be orally administered.
干预措施: Spironolactone Tablets (Test) (Drug)
Reference product
Active Comparator
ALDACTONE® Tablets,100 mg/tablet, to be orally administered.
干预措施: Spironolactone Tablets (Reference) (Drug)
结局指标
主要结局
Cmax
时间窗: up to 24 hours after tablet intake
Maximum Observed Concentration in Plasma
AUC 0-t
时间窗: up to 24 hours after tablet intake
Area Under the Concentration-time Curve From Time Zero to Time of Last
AUC 0-∞
时间窗: up to 24 hours after tablet intake
Area Under the Concentration-time Curve From Time Zero to Infinity
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Trial to Evaluate Bioequivalence of LCB01-0371 in Different BatchesHealthyNCT04939779LigaChem Biosciences, Inc.25
已完成
1 期
Bioequivalence Study of Levetiracetam Tablet and Intravenous Infusion in Healthy Japanese SubjectsHealthy VolunteersNCT01394224UCB Pharma25
已完成
早期 1 期
Comparative Bioavailability Study of TAH3311 5 mg Oral Dissolving Film vs ELIQUIS® 5 mg Tablet in Healthy VolunteersHealthy VolunteersFastingFedNCT05995119TAHO Pharmaceuticals Ltd.12
已完成
1 期
Study to Assess Bioequivalence of a New Nifurtimox Oral Tablet FormulationBioequivalenceNCT03708133Bayer24
已完成
1 期
A Study to Evaluate Zilucoplan Injected Subcutaneously Either by a Prefilled Syringe or an Auto-injector in Healthy Adult ParticipantsHealthy VolunteersNCT06511076UCB Biopharma SRL14